<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115151">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604122</url>
  </required_header>
  <id_info>
    <org_study_id>B3461036</org_study_id>
    <nct_id>NCT01604122</nct_id>
  </id_info>
  <brief_title>Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers</brief_title>
  <official_title>Cross-sectional, Non-interventional Burden Of Disease (Bod) Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (Ttr-fap) Or Transthyretin Cardiomyopathy (ttr-cm) And Caregivers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an online (web-based) or paper-based survey for patients with transthyretin
      familial amyloidosis polyneuropathy (TTR-FAP) and caregivers. The results will be used to
      describe the emotional, physical, and financial impact of having TTR-FAP or caring for
      someone who has the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Convenience sample of patients and caregivers recruited through patient advocacy groups.
      Convenience sample.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SF-12 physical and mental health summary scores and subscale scores (Physical functioning, Role-physical, Bodily pain, General health, Vitality, Social functioning, Role-emotional, and Mental health)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS) depression and anxiety subscale scores</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>EuroQoL-5 Dimensions (EQ-5D-3L) utility (index) score and visual analog scale (EQ-VAS) score</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Work Productivity and Activities Impairment: Specific Health Version (WPAI-SH) - Four component score for absenteeism, presenteeism (reduced productivity while at work), overall work impairment and impairment in activities performed outside of work</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Caregiver burden items as assessed by number of hours spent caring for TTR-FAP patient, work time lost, impact on work productivity, and costs.</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) total score (TQOL) and subscale scores (Symptoms, ADLs, Small fiber, Large fiber, Autonomic)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain items (3 items: right now, average in past week, and worst in past week)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Zarit Burden Interview (ZBI) total score and subscale scores (Burden in the relationship, Emotional Well-being, Social and family life, Finances, Loss of control over one's life)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Healthcare resource use (HCRU): Visits to doctors, hospitals, and other treatments. Healthcare resource use for caregivers will be assessed using an abbreviated version.</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ) subscale scores</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP)</condition>
  <condition>Transthyretin Cardiomyopathy (TTR-CM)</condition>
  <condition>Familial Amyloid Cardiomyopathy</condition>
  <condition>Senile Systemic Amyloidosis (SSA)</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caregivers</arm_group_label>
    <description>Caregivers who are taking care of patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No drug</intervention_name>
    <description>No drug.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No drug</intervention_name>
    <description>No drug.</description>
    <arm_group_label>Caregivers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults (ages 18-85 years inclusive) diagnosed with TTR-FAP or TTR-CM and experiencing
        symptoms or currently providing care for a patient with TTR-FAP or TTR-CM
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (ages 18-85 years inclusive) diagnosed with TTR-FAP or TTR-CM and experiencing
             symptoms or currently providing care for a patient with TTR-FAP or TTR-FAP

        Exclusion Criteria:

          -  Caregivers who formally care for a TTR-FAP or TTR-CM patient as part of their job
             description and receive payment for their services.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461036</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 6, 2015</lastchanged_date>
  <firstreceived_date>May 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Survey</keyword>
  <keyword>burden of illness</keyword>
  <keyword>caregivers</keyword>
  <keyword>TTR-FAP</keyword>
  <keyword>TTR-CM</keyword>
  <keyword>familial amyloid polyneuropathy</keyword>
  <keyword>observational</keyword>
  <keyword>transthyretin familial amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloidosis, Familial</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
